Education
About Us
Working with TipRanks
Follow Us
Emergent Biosolutions (EBS)
NYSE:EBS
Earnings Data
Report Date
Apr 24, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.49Last Year’s EPS
0.59Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: -24.30%
|Next Earnings Date:Apr 24, 2025
Earnings Call Sentiment|Neutral
The earnings call presented significant achievements in financial stability and operational efficiency, highlighted by debt reduction and cost savings. However, revenue challenges, including a decline in NARCAN sales and conservative future guidance, indicate ongoing challenges. The sentiment is balanced with notable improvements offset by revenue pressures.Company Guidance
During the fourth quarter and full year 2024 earnings call, Emergent BioSolutions provided guidance for 2025, highlighting a conservative revenue forecast due to administrative transitions, with total revenue projected between $750 million and $850 million. They expect adjusted EBITDA to be in the range of $150 million to $200 million, indicating a strong margin improvement despite a lower top-line revenue. Key metrics from 2024 included total revenues of $1.04 billion and adjusted EBITDA of $183 million, with significant improvements in gross margin and a reduction in operating expenses by $130 million. The company also announced a strategic focus on their medical countermeasure (MCM) products and NARCAN nasal spray, with 2024 sales of 11 million two-dose cartons distributed across the US and Canada. They reported a net debt reduction of $156 million, ending the year with $200 million in liquidity. For 2025, they anticipate continued operational cash flow growth and strategic capital deployment to drive long-term profitable growth.Debt Reduction and Financial Stability
Emergent BioSolutions Inc. reduced net debt by $156 million (21%) and improved the balance sheet, extending debt maturity to 2029.
Improved Profitability and Cost Savings
Operating expenditures were reduced by $130 million, with a total of $250 million in savings over two years. Adjusted EBITDA improved to $183 million from a negative $22 million in 2023.
NARCAN Distribution and Market Leadership
Distributed 11 million two-dose cartons of NARCAN across the US and Canada, maintaining a 75% market share in the growing naloxone nasal spray market.
Strong Contract Awards and BioDefense Performance
Secured $550 million in MCM contract awards and maintained strong performance in biodefense product sales including anthrax and smallpox vaccines.
---
EBS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EBS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $6.83 | $6.39 | -6.44% |
| Nov 06, 2024 | $9.20 | $11.00 | +19.57% |
| Aug 06, 2024 | $9.86 | $5.72 | -41.99% |
| May 01, 2024 | $1.93 | $3.30 | +70.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Emergent Biosolutions (EBS) report earnings?
Emergent Biosolutions (EBS) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
What is Emergent Biosolutions (EBS) earnings time?
Emergent Biosolutions (EBS) earnings time is at Apr 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EBS EPS forecast?
EBS EPS forecast for the fiscal quarter 2025 (Q1) is 0.49.
---